stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.18
0.82
+4.72%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) EBITDA
Dyne Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$468.0M, compared with −$345.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$536.1M. Over the past ten years it has ranged from −$468.0M (fiscal 2025) to −$4.8M (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Dyne Therapeutics, Inc. ranks 582nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$468.0M | — |
| FY2024 | −$345.8M | — |
| FY2023 | −$241.6M | — |
| FY2022 | −$168.0M | — |
| FY2021 | −$146.4M | — |
| FY2020 | −$57.9M | — |
| FY2019 | −$13.6M | — |
| FY2018 | −$4.8M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$181.3M | — |
| Mar 2026 | −$125.0M | — |
| Dec 2025 | −$116.0M | — |
| Sep 2025 | −$113.7M | — |
| 23 more quarters | Free account |
Against its own ten years
Low −$468.0M
High −$4.8M
Ten-year median
−$157.2M
Current reading's percentile
13
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| ELVN Enliven Therapeutics, Inc. compare | −$123.8M |
| CELC Celcuity, Inc. compare | −$204.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$474.6M |
| DNLI Denali Therapeutics Inc. compare | −$524.5M |
| DYN Dyne Therapeutics, Inc. | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item